Diverging Views Emerge on Medtronic's Stock Trajectory

Medtronic beats Q3 estimates but cuts full-year EPS guidance due to MiniMed charges, sparking a sharp analyst split and stock decline near 52-week lows.

Financial analysts are presenting starkly contrasting outlooks for Medtronic following the company's latest quarterly results. While the medical device giant surpassed Wall Street's expectations for its third quarter, a more cautious full-year forecast has ignited a debate, primarily centered on the impact of its MiniMed subsidiary.

Operational Performance Versus Forward Guidance

Medtronic reported a solid operational performance for the third quarter, with revenue reaching $9.0 billion, a figure that edged past market forecasts. However, the company's updated guidance for fiscal 2026 has become a focal point for investor concern. Management now anticipates adjusted earnings per share to land between $5.50 and $5.54, a revision from the previous top-end expectation of $5.66.

This downward adjustment is largely attributed to one-time factors within its MiniMed business. A $157 million payment scheduled for the fourth quarter, coupled with dilution effects stemming from the partial public offering of MiniMed, are expected to pressure near-term results. The company maintains that these are isolated charges, but the market's reaction suggests lingering skepticism.

Analyst Consensus Shatters

The revised guidance has led to a significant split in analyst sentiment. On one side, Barclays reaffirmed an Overweight rating and increased its price target from $118 to $120, positioning it as one of the more bullish views on the street. Conversely, Piper Sandler adopted a notably more cautious stance, reducing its price target substantially from $105 to $91 while maintaining a Neutral rating. The current average analyst price target sits at approximately $110, highlighting the wide dispersion of opinions.

Market Reaction and Technical Pressure

This uncertainty is being directly reflected in the share price. The stock has faced considerable selling pressure, declining nearly 11% over the past 30 trading days. Currently trading around €74.15, it is approaching its 52-week low of €71.00, a level that is now drawing increased attention from market participants.

The path forward for Medtronic's equity appears contingent on a single, critical factor: execution. Restoring investor confidence will require the company to demonstrably achieve its newly set earnings targets and convincingly prove that the financial headwinds from MiniMed are, indeed, temporary. Until then, the stock may struggle to find a stable footing.